Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 017.5 JPY -2.23% Market Closed
Market Cap: 2.3T JPY

Olympus Corp
Investor Relations

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes.

Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Aug 8, 2025
AI Summary
Q1 2026

Revenue Decline: Olympus reported a 12% year-on-year drop in consolidated revenue to JPY 206.5 billion for Q1, falling short of expectations.

Profit Down: Adjusted operating profit fell 65% year-on-year to JPY 13.2 billion, with margins pressured by declining sales and higher SG&A expenses.

US Market Challenges: US GIS division saw an 18% sales decline, attributed to tough prior-year comparisons and purchase delays ahead of new product launches like the EDOF scope.

Guidance Cut: Full-year revenue and operating profit forecasts were revised downward to reflect US tariffs, FDA import alerts, and ongoing market softness.

Cost Controls: Management is intensifying cost discipline, aiming to keep SG&A growth below revenue growth and implement structural reforms.

FDA & Quality: Project Elevate addressing FDA warning letters is 96% complete; inspections are pending, but no additional Elevate-related costs are expected this year.

Innovation Focus: Launch of new products (EDOF scope, EU-ME3, Slim EBUS, VISERA ELITE III, THUNDERBEAT II) and creation of Swan EndoSurgical JV highlight a strategic push into robotics and AI.

China & Japan Weakness: Business in China remains challenged by the Buy China policy and in Japan by persistent hospital budget constraints, with local manufacturing planned to support recovery.

Key Financials
Revenue
JPY 206.5 billion
Adjusted Operating Profit
JPY 13.2 billion
Adjusted Operating Margin
6.4%
Operating Profit
JPY 16.6 billion
Gastrointestinal Solutions Adjusted Operating Profit
JPY 20.1 billion
Gastrointestinal Solutions Adjusted Operating Margin
14.5%
Surgical and Interventional Solutions Adjusted Operating Loss
JPY 1.3 billion
Cash and Cash Equivalents
JPY 241.2 billion
Equity Ratio
50.8%
Cash Flow from Operating Activities
negative JPY 15.2 billion
Cash Flow from Investing Activities
minus JPY 17.5 billion
Free Cash Flow
negative JPY 32.7 billion
Adjusted Free Cash Flow
negative JPY 70.5 billion
Full-Year Revenue Guidance
JPY 998 billion
Full-Year Adjusted Operating Profit Guidance
JPY 157 billion
Full-Year Adjusted Operating Margin Guidance
15.7%
Profit Attributable to Owners of Parent
JPY 94 billion
EPS
JPY 85
Dividend (year-end)
JPY 30 per share
Share Buyback
JPY 50 billion
US Tariffs Net Impact (FY 2026)
JPY 16 billion
FDA Import Alert Revenue Impact (FY 2026)
JPY 15 billion
Project Elevate Costs (FY 2026)
JPY 20 billion (JPY 10 billion SG&A, JPY 10 billion other costs)
Earnings Call Recording
Other Earnings Calls

Management

Mr. Yasuo Takeuchi
Representative Executive Officer, ESG Officer & Executive Chairman
No Bio Available
Mr. Andre Roggan
Executive Officer & CTO
No Bio Available
Mr. Tetsuo Kobayashi
Executive Officer and Chief Manufacturing & Supply Officer
No Bio Available
Mr. Frank Drewalowski
Executive Officer & Endoscopic Solutions Division Head
No Bio Available
Ms. Gabriela Kaynor
Executive Officer & Chief Strategy Officer
No Bio Available
Tatsuya Izumi
Executive Officer & CFO
No Bio Available
Stephen Kneebone
Corporate Officer & Chief Information Officer
No Bio Available
Mr. Takaaki Sakurai
Vice President of Investor Relations
No Bio Available
Mr. Neil Boyden Tanner
Executive Officer & Global General Counsel
No Bio Available
Shigeto Ohtsuki
Executive Officer & Chief Human Resources Officer
No Bio Available

Contacts

Address
TOKYO-TO
Shinjuku
Shinjuku Monolith, 2-3-1, Nishi-Shinjuku
Contacts
+81333402111.0
www.olympus.co.jp